MPS Powered by Eureka

Submission Tilte

Navigating the Frontier: Probiotics' Promising Path in Combatting Viral Respiratory Infections, Spotlight on Coronaviridae.

Submission Abstract:

Probiotics, well-known for their role in gut health, show promise in preventing and managing respiratory virus infections, particularly in children and at-risk populations. However, the profound influence of novel pathogenic viral RTIs such as coronaviruses has reshaped perspectives on the potential of probiotics. Despite their potential, significant gaps remain in our understanding, including the viral types and strain-specific effects, mechanisms of action, role of the gut-lung axis, clinical efficacy, population-specific impacts, interactions with other treatments, and long-term safety. The gut-lung axis, which facilitates communication between the gut and the lungs through the immune system, the microbiota, and signaling pathways, plays a key role in shaping function and composition. This connection is crucial in understanding how probiotics may aid in preventing and treating respiratory virus infections by modulating inflammatory responses. However, more research is needed to understand these mechanisms and develop targeted probiotic therapies. Probiogenomics is an emerging field that integrates genomics with various omics disciplines, providing a comprehensive approach to understanding the host-microbiome relationship and the functionality of probiotics. To address these knowledge gaps and maximise probiotics' potential in respiratory health, a multidisciplinary approach involving microbiologists, immunologists, clinicians, and epidemiologists is essential in producing high-quality studies. Collaboration in these fields is crucial to unraveling the intricate mechanisms that underlie the efficacy and optimise their use in clinical settings, thus improving respiratory health outcomes.